LOGIN  |  REGISTER
C4 Therapeutics
C4 Therapeutics

Talkspace to Participate in the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023 | Last Trade: US$3.04 0.13 -4.10

NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Talkspace (Nasdaq: TALK), a leading behavioral healthcare company, today announced that Dr. Jon R. Cohen, Chief Executive Officer, and Jennifer Fulk, Chief Financial Officer, will participate in the 41st Annual J.P. Morgan Healthcare Conference, including a presentation on Thursday, January 12, 2023 at 11:15 a.m. PST. Presentation materials will be available online at https://investors.talkspace.com/.

About Talkspace

Talkspace (NASDAQ: TALK) is a leading virtual behavioral healthcare company committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall health and should be available to everyone.

Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services from self-guided products to individual and couples therapy, in addition to psychiatric treatment and medication management. With Talkspace’s core psychotherapy offering, members are matched with one of thousands of licensed providers across all 50 states and can choose from a variety of subscription plans including live video, text or audio chat sessions and/or unlimited, asynchronous text messaging.

All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. Talkspace covered approximately 86 million lives at September 30, 2022, through our partnerships with insurance and employee assistance programs or other network behavioral health paid benefit programs.

For more information, visit www.talkspace.com.

Contacts

‍For Investors:
Jeannine Feyen
Director, Communications
(917) 748-5325
This email address is being protected from spambots. You need JavaScript enabled to view it.

For Media:
SKDK
John Kim
(310) 997-5963
This email address is being protected from spambots. You need JavaScript enabled to view it.


Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB